Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 feb 2016 - 07:00
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma - Disclosure of Home Member State
Bericht
Amsterdam, The Netherlands, February 19, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that following the amendment of the Dutch Financial Supervision Act (FSA) as a result of the implementation of the (amended) European Union’s so-called Transparency Directive, the Company is required to disclose its home Member State. In accordance with FSA Section 5:25a, the Company herewith announces that its home Member State is the Netherlands.
Datum laatste update: 27 maart 2025